All In Biotech

NDA 050592 · Sandoz

Tobradex

Dexamethasone, Tobramycin · Ophthalmic · Aminoglycoside Antibacterial; Corticosteroid

Last checked: Nov 19, 2026Latest source record: Apr 7, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1988

Aug 18, 1988

Approved uses

1

Original approval plus efficacy supplements

Registered trials

4,222

936 Phase 3, 495 recruiting

FAERS reports

3,324

2,271 serious, 150 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 11, 2026.

INDICATIONS AND USAGE: Tobramycin and dexamethasone ophthalmic suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains. Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae . Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species.

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 18, 1988 Original approval · Type 4 - New Combination
1 products under this application
  • TOBRADEX · DEXAMETHASONE 0.1%; TOBRAMYCIN 0.3% · SUSPENSION/DROPS, OPHTHALMIC · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Dexamethasone" as an intervention, any sponsor and status, largest first.

All 4,222 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • eye pain243
  • off label use226
  • drug ineffective184
  • vision blurred182
  • headache179
  • ocular hyperaemia170
  • eye irritation169
  • nausea168
  • fatigue165
  • dizziness143
  • pain137
  • diarrhoea135

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20048
200523
200644
200730
200841
200959
201058
201177
201293
201374
201495
2015147
2016201
2017168
2018321
2019268
2020258
2021254
2022241
2023238
2024236
2025200
2026190

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tobradex (Tobramycin/Dexamethasone)

2024 spending

$15.5M

Beneficiaries

41,104

56,574 claims

Per beneficiary

$378

$75.94 per unit

View as table
YearSpending
2020$0
2021$6,080,194
2022$14,045,999
2023$15,763,258
2024$15,521,271

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 7,425 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.